Cidara Therapeutics (CDTX) Stock Price, News & Analysis

Company Overview

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

Key Stats

• Today's Range: $17.41 to $18.96
• 50-Day Range: $10.17 to $20.40
• 52-Week Range: $10.00 to $24.40
• Volume: 62,747 shs
• Average Volume: 63,127 shs
• Market Capitalization: $124.86 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $30.50
• Consensus Rating: Buy

Cidara Therapeutics Stock Analysis - MarketRank™

Cidara Therapeutics scored higher than 90% of companies evaluated by MarketBeat, and ranked 131st out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Cidara Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Cidara Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Cidara Therapeutics are expected to decrease in the coming year, from ($8.74) to ($14.39) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cidara Therapeutics is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cidara Therapeutics is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.92% of the float of Cidara Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Cidara Therapeutics has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cidara Therapeutics has recently decreased by 22.91%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cidara Therapeutics does not currently pay a dividend.

Dividend Growth

Cidara Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.6 / 5
• Environmental Score: -0.85

Percentage of Shares Shorted

0.92% of the float of Cidara Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Cidara Therapeutics has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cidara Therapeutics has recently decreased by 22.91%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 1.44

News Sentiment

Cidara Therapeutics has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Cidara Therapeutics this week, compared to 2 articles on an average week.

Search Interest

2 people have searched for CDTX on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Cidara Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,755.00 in company stock.

Percentage Held by Insiders

Only 7.64% of the stock of Cidara Therapeutics is held by insiders.

Percentage Held by Institutions

Only 35.82% of the stock of Cidara Therapeutics is held by institutions.

CDTX Stock Analysis - Frequently Asked Questions

How have CDTX shares performed this year?

Cidara Therapeutics' stock was trading at $15.88 at the beginning of 2024. Since then, CDTX shares have increased by 11.5% and is now trading at $17.71.
View the best growth stocks for 2024 here.

How were Cidara Therapeutics' earnings last quarter?

Cidara Therapeutics, Inc. (NASDAQ:CDTX) released its quarterly earnings results on Wednesday, November, 10th. The biotechnology company reported ($7.40) EPS for the quarter, missing the consensus estimate of ($7.20) by $0.20. The biotechnology company earned $7.08 million during the quarter, compared to analysts' expectations of $3.62 million. Cidara Therapeutics had a negative net margin of 289.05% and a negative trailing twelve-month return on equity of 69.64%.

When did Cidara Therapeutics' stock split?

Shares of Cidara Therapeutics reverse split on Wednesday, April 24th 2024. The 1-20 reverse split was announced on Wednesday, April 24th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, April 24th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

When did Cidara Therapeutics IPO?

Cidara Therapeutics (CDTX) raised $60 million in an IPO on Wednesday, April 15th 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Jefferies and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow Life Sciences, Needham and BTIG were co-managers.

Who are Cidara Therapeutics' major shareholders?

Cidara Therapeutics' top institutional investors include RA Capital Management L.P. (9.97%), Checkpoint Capital L.P. (2.59%) and Geode Capital Management LLC (0.75%). Insiders that own company stock include Jeffrey Stein, Taylor Sandison, Leslie Tari, Preetam Shah, Paul Daruwala, Shane Ward and Brady Johnson.
View institutional ownership trends.

How do I buy shares of Cidara Therapeutics?

Shares of CDTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Cidara Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cidara Therapeutics investors own include Meta Platforms (META), VBI Vaccines (VBIV), SCYNEXIS (SCYX), NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Sorrento Therapeutics (SRNE) and Inovio Pharmaceuticals (INO).

Company Calendar

• Last Earnings: 11/10/2021
• Today: 12/04/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 4/28/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CDTX
• CUSIP: N/A
• CIK: 1610618
• Web: www.cidara.com
• Phone: (858) 752-6170
• Fax: N/A
• Employees: 90
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $30.50
• High Stock Price Target: $40.00
• Low Stock Price Target: $24.00
• Potential Upside/Downside: +72.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.20
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($25.52)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-22,930,000.00
• Net Margins: -289.05%
• Pretax Margin: -514.62%
• Return on Equity: -69.64%
• Return on Assets: -33.73%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.54
• Quick Ratio: 3.54

Sales & Book Value

• Annual Sales: $63.90 million
• Price / Sales: 1.95
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.82) per share
• Price / Book: -9.73

Miscellaneous

• Outstanding Shares: 7,050,000
• Free Float: 6,509,000
• Market Cap: $124.86 million
• Optionable: Optionable
• Beta: 1.13